Wells Fargo Raises Abbott Laboratories (ABT) Price Target to $119

Wells Fargo maintained its Overweight rating on Abbott Laboratories (NYSE: ABT) on October 22, 2026, while raising its price target on the stock from $112.00 to $119.00. The research note arrived alongside a flurry of updates from other major Wall Street firms evaluating the healthcare giant.

ABT Abbott Laboratories

$100.51 ▼ -17.06% year to date

1M 3M YTD

Daily close · Oct 21, 2026

Wells Fargo's Call on Abbott Laboratories

In its October 22 note, Wells Fargo reaffirmed its Overweight stance on the medical devices maker and lifted the target by $7.00. The firm's target sits below where shares recently changed hands, reflecting a measured outlook compared to the broader analyst consensus.

Other Institutional Activity in Abbott Laboratories

Large institutional funds continue to adjust their holdings in the medical products firm. Capital International Investors reduced its stake by 2,842,222 shares, ending its reported period with 34,654,113 shares valued at about $3.55 billion.

Abbott Laboratories Stock Down 0.1%

Abbott Laboratories recently traded around $102.35 as of October 22, down about 0.2% from its session close of $102.56. The stock sits roughly 3.0% below its 50-day moving average of $105.49 and about equal to its 200-day moving average of $102.46. Shares trade 22.5% below their 52-week high of $132.03 and 24.9% above their 52-week low of $81.97. The current share price sits about 15.0% below the analyst mean price target of $120.41.

Recent Earnings

Abbott Laboratories posted trailing-twelve-month revenue of $46.58 billion with earnings of $2.69 per share. The company generated a net profit margin of 11.6% and a return on equity of 10.6%, accompanied by year-over-year revenue growth of 13.0%. The company operates across four primary business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.

Dividend

Abbott Laboratories pays an annual dividend rate of $2.52 per share, offering a dividend yield of 2.46% based on a payout ratio of 78.7%.

Insider Buying and Selling at Abbott Laboratories

Company insiders have transacted shares throughout the year. Director John G. Stratton bought 2,000 shares on May 7 at $86.82 apiece for a total value of $173,640. On the selling side, officer Louis H Morrone disposed of 5,850 shares on August 11 at $109.83 per share worth $642,506. Chief Executive Officer Robert B. Ford sold 398,832 shares on August 25 valued at $46.2 million, and officer John A. Mccoy Jr sold 27 shares on September 2 at $109.54 each for a total of $2,958.

Analysts Set New Price Targets

Wall Street firms updated their views on October 22 alongside Wells Fargo. RBC Capital maintained an Outperform rating while lowering its target from $130.00 to $125.00. JP Morgan kept an Overweight rating and trimmed its target from $120.00 to $118.00. TD Cowen maintained a Buy rating while cutting its target from $135.00 to $118.00. Baird maintained an Outperform rating and raised its target from $121.00 to $123.00. Across the broader analyst community, the stock carries a consensus recommendation key of strong_buy from 26 analysts, with a target high price of $135.00 and a target low of $103.00.

About Abbott Laboratories

Based in Abbott Park, Illinois, Abbott Laboratories discovers, develops, manufactures, and sells health care products globally. The firm serves hospitals, laboratories, and consumers through its diverse medical device and pharmaceutical offerings, employing roughly 122,000 people worldwide.

Bottom Line

Wells Fargo's updated price target places fresh focus on how medical device makers navigate current market valuations. Investors will watch upcoming quarterly reports and institutional disclosures to gauge whether shares can close the gap toward Wall Street's higher targets.